Biocryst Pharmaceuticals Stock Investor Sentiment

BCRX Stock  USD 7.98  0.29  3.77%   
Slightly above 55% of BioCryst Pharmaceuticals' investors are presently thinking to get in. The analysis of the overall investor sentiment regarding BioCryst Pharmaceuticals suggests that some traders are interested. BioCryst Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, BioCryst Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
  
a minute ago at gurufocus.com         
Q4 2024 BioCryst Pharmaceuticals Inc Earnings Call Transcript
Gurufocus Stories at Macroaxis
23 hours ago at thelincolnianonline.com         
Hillsdale Investment Management Inc. Increases Stock Position in BioCryst Pharmaceuticals, Inc.
news
2 days ago at thelincolnianonline.com         
BioCryst Pharmaceuticals, Inc. Given Consensus Recommendation of Moderate Buy by Brokerages
news
few days ago at bizjournals.com         
North Carolina biotech sues over potential billion-dollar drug
bizjournals News
few days ago at simplywall.st         
The 4.9 percent return this week takes BioCryst Pharmaceuticals shareholders five-year gains to 295
Simply Wall St News at Macroaxis
few days ago at finance.yahoo.com         
Institutional investors control 75 percent of BioCryst Pharmaceuticals, Inc. and were rewarded last ...
Yahoo News
over a week ago at thelincolnianonline.com         
BioCryst Pharmaceuticals, Inc. Shares Purchased by Jupiter Asset Management Ltd.
news
over a week ago at news.google.com         
25,583 Shares in BioCryst Pharmaceuticals, Inc. Bought by Proficio Capital Partners LLC - Defense Wo...
Google News at Macroaxis
over a week ago at thelincolnianonline.com         
E Fund Management Co. Ltd. Sells 7,226 Shares of BioCryst Pharmaceuticals, Inc.
news
over two weeks ago at gurufocus.com         
BioCryst Pharmaceuticals Inc Announces Grant of Restricted Stock Units to New Employees
Gurufocus Stories at Macroaxis
over two weeks ago at gurufocus.com         
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635
Gurufocus Stories at Macroaxis
over two weeks ago at globenewswire.com         
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635
Macroaxis News: globenewswire.com
over two weeks ago at finance.yahoo.com         
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635
Yahoo News
over two weeks ago at seekingalpha.com         
BioCryst falls 8 percent following CFO departure announcement
seekingalpha News
over two weeks ago at seekingalpha.com         
Acquisition by Milano Vincent of 653 shares of BioCryst Pharmaceuticals at 8.61 subject to Rule 16b-...
seekingalpha News
Far too much social signal, news, headlines, and media speculation about BioCryst Pharmaceuticals that are available to investors today. That information is available publicly through BioCryst media outlets and privately through word of mouth or via BioCryst internal channels. However, regardless of the origin, that massive amount of BioCryst data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of BioCryst Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of BioCryst Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to BioCryst Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive BioCryst Pharmaceuticals alpha.

BioCryst Pharmaceuticals Performance against Dow Jones

 Price Growth (%)  
       Timeline  

Additional Tools for BioCryst Stock Analysis

When running BioCryst Pharmaceuticals' price analysis, check to measure BioCryst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioCryst Pharmaceuticals is operating at the current time. Most of BioCryst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of BioCryst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioCryst Pharmaceuticals' price. Additionally, you may evaluate how the addition of BioCryst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.